CBER-CDER Transition: FDA Creating Template For Product Review Transfer
Executive Summary
FDA is creating a template to help it decide what products should be transferred from the Center for Biologics Evaluation & Research to the Center for Drug Evaluation & Research under its proposed reorganization
You may also be interested in...
CBER/CDER Reorganization: Product Transfer Set, Resources Under Review
The CBER/CDER reorganization working group is finalizing a list of approved and investigational products whose reviews would be shifted from the Center for Biologics Evaluation & Research to the Center for Drug Evaluation & Research
CBER/CDER Reorganization: Product Transfer Set, Resources Under Review
The CBER/CDER reorganization working group is finalizing a list of approved and investigational products whose reviews would be shifted from the Center for Biologics Evaluation & Research to the Center for Drug Evaluation & Research
FDA Needs Five Centers, Crawford Says; CBER Centennial Is Emotional Affair
FDA's five-center structure does not need consolidation beyond the agency's plan to shift biological therapeutic reviews from the Center for Biologics Evaluation & Research to the Center for Drug Evaluation & Research, Acting Commissioner Lester Crawford, PhD, said